封面
市场调查报告书
商品编码
1594381

多发性硬化症市场:按治疗方式、按应用划分 - 2025-2030 年全球预测

Multiple Sclerosis Market by Treatment Modality (Injectable Agents, Oral Agents), Application (Hospital, Research) - Global Forecast 2025-2030

出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年多发性硬化症市值为166.9亿美元,预计到2024年将达到180.5亿美元,复合年增长率为8.25%,预计到2030年将达到290.9亿美元。

多发性硬化症 (MS) 是一种影响中枢神经系统的慢性自体免疫疾病,其症状从轻微(如麻木)到严重(如瘫痪和视力丧失)不等。 MS 市场范围包括旨在管理症状和改变疾病进展的药物、诊断和支持性护理技术。透过多发性硬化症治疗来改善患者的生活品质和减缓疾病进展的需求已成为世界各地医疗保健系统不可或缺的一部分。治疗方法包括干扰素等疾病修正治疗、症状治疗和先进的诊断影像,最终用途主要在医院、诊所和居家医疗。市场成长受到诊断率上升、治疗技术进步和老年人口增加的显着影响。市场上的最新机会围绕着个人化医疗、基因治疗和新型单株抗体。建议投资研发并与生技公司建立策略联盟,以抓住这些机会。然而,高昂的治疗成本、复杂的医药品认证过程以及发展中地区的认知度低等挑战正在阻碍成长。此外,市场参与企业还面临学名药和生物相似药的竞争,利润空间受到挤压。成熟的创新领域包括用于早期诊断的生物标记开发、人工智慧驱动的患者管理系统以及具有成本效益的药物製造流程,为业务成长提供了新的途径。儘管该市场具有很高的成长潜力,但其性质意味着它受到严格的监管监督,并且在治疗开发中必须考虑道德因素。为了克服这些挑战,企业应专注于全球策略扩张,加强与研究机构的合作,并优先考虑以患者为中心的产品交付方法。注重教育和宣传还可以帮助公司扩大市场范围,并确保多发性硬化症治疗在竞争激烈的环境中持续成长。

主要市场统计
基准年[2023] 166.9亿美元
预测年份 [2024] 180.5亿美元
预测年份 [2030] 290.9亿美元
复合年增长率(%) 8.25%

市场动态:揭示快速发展的多发性硬化症市场的关键市场洞察

供需的动态交互作用正在改变多发性硬化症市场。透过了解这些不断变化的市场动态,公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险,同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 对全球研发活动的大力投资
    • 政府支持提高公众意识
    • 年轻人和老年人族群多发性硬化症的发生率不断上升
  • 市场限制因素
    • 药品价格相对较高
  • 市场机会
    • 对 Copaxone 和Tysabri等口服药物的偏好日益增加
    • 主要企业新药研发管线的出现
  • 市场挑战
    • 严格的药品核准监理政策

波特的五力:驾驭多发性硬化症市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势,解决弱点并避免潜在的挑战,从而确保更强大的市场地位。

PESTLE分析:了解多发性硬化症市场的外部影响

外部宏观环境因素在塑造多发性硬化症市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素,公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化,并为他们做出积极主动的决策做好准备。

市场占有率分析 了解多发性硬化症市场的竞争格局

对多发性硬化症市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势,为供应商提供了製定策略决策所需的洞察力,使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵多发性硬化症市场供应商的绩效评估

FPNV定位矩阵是评估多发性硬化症市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商,从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商,以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议绘製多发性硬化症市场的成功之路

多发性硬化症市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过考虑关键资源、能力和绩效指标,公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战,利用新的商机,并取得长期成功。

本报告对市场进行了全面分析,涵盖关键重点领域:

1. 市场渗透率:对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓:辨识新兴市场的成长机会,评估现有领域的扩张潜力,并提供未来成长的策略蓝图。

3. 市场多元化:分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报:彻底分析竞争格局,检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新:重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题,帮助相关人员做出明智的决策:

1.目前的市场规模和未来的成长预测是多少?

2. 哪些产品、区隔市场和地区提供最佳投资机会?

3.塑造市场的主要技术趋势和监管影响是什么?

4.主要厂商的市场占有率和竞争地位如何?

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么?

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 对全球研发活动的积极投资
      • 政府的有利支持以提高公众意识
      • 年轻人和老年人多发性硬化症的发生率上升
    • 抑制因素
      • 药品费用相对较高
    • 机会
      • Copaxone 和Tysabri等口服药物越来越受到青睐。
      • 主要市场参与者新药管道的出现
    • 任务
      • 严格的药品核准监理政策
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依治疗方法的多发性硬化症市场

  • 注射
  • 口服剂

第七章 多发性硬化症市场:依应用分类

  • 医院
  • 调查

第八章美洲多发性硬化症市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区多发性硬化症市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章欧洲、中东和非洲多发性硬化症市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵,2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Allergan PLC
  • AstraZeneca PLC
  • Bayer AG
  • Biogen Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Merck & Co. Inc.
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Synthetic Biologics, Inc.
  • Teva Pharmaceuticals Industries Ltd.
Product Code: MRR-036C5CF3A89D

The Multiple Sclerosis Market was valued at USD 16.69 billion in 2023, expected to reach USD 18.05 billion in 2024, and is projected to grow at a CAGR of 8.25%, to USD 29.09 billion by 2030.

Multiple Sclerosis (MS) is a chronic autoimmune disorder affecting the central nervous system, characterized by symptoms ranging from mild, such as numbness, to severe, such as paralysis or loss of vision. The market scope for MS involves pharmaceuticals, diagnostics, and supportive care technologies aimed at managing symptoms and modifying disease progression. The necessity of MS treatments lies in improving patient quality of life and slowing disease progression, making them indispensable in healthcare systems worldwide. Applications include disease-modifying therapies like interferons, symptomatic treatments, and advanced imaging diagnostics, with primary end-use spanning hospitals, clinics, and home care settings. Market growth is heavily influenced by increased diagnosis rates, technological advancements in treatment, and a growing elderly population. The latest opportunities in the market revolve around personalized medicine, gene therapies, and novel monoclonal antibodies. To seize these opportunities, investment in R&D and strategic partnerships with biotech firms are recommended. However, challenges such as high treatment costs, complex drug approval processes, and limited awareness in developing regions hinder growth. Moreover, market players face competition from generic drugs and biosimilars, compressing profit margins. Areas ripe for innovation include biomarker development for early diagnosis, AI-driven patient management systems, and cost-effective drug manufacturing processes, offering new business growth avenues. Despite the robust growth potential, the market's nature is characterized by high regulatory scrutiny and ethical considerations in treatment developments. To navigate these challenges, firms should focus on global strategic expansion, enhance collaboration with research institutions, and prioritize patient-centric approaches in their product offerings. By emphasizing education and advocacy, companies can also broaden market reach and ensure sustained growth in the competitive landscape of MS treatments.

KEY MARKET STATISTICS
Base Year [2023] USD 16.69 billion
Estimated Year [2024] USD 18.05 billion
Forecast Year [2030] USD 29.09 billion
CAGR (%) 8.25%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Multiple Sclerosis Market

The Multiple Sclerosis Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Robust investment in research and development activities globally
    • Favorable government support to increase the awareness among people
    • Rising incidence of MS in young and elderly people
  • Market Restraints
    • Relatively high cost of the drugs
  • Market Opportunities
    • Increasing preference for oral drugs such as Copaxone and Tysabri
    • Emerging novel pipeline of drugs by key market players
  • Market Challenges
    • Stringent regulatory policies for drug approval

Porter's Five Forces: A Strategic Tool for Navigating the Multiple Sclerosis Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Multiple Sclerosis Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Multiple Sclerosis Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Multiple Sclerosis Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Multiple Sclerosis Market

A detailed market share analysis in the Multiple Sclerosis Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Multiple Sclerosis Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Multiple Sclerosis Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Multiple Sclerosis Market

A strategic analysis of the Multiple Sclerosis Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Multiple Sclerosis Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Allergan PLC, AstraZeneca PLC, Bayer AG, Biogen Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Merck & Co. Inc., Mylan N.V., Novartis AG, Pfizer Inc., Sanofi S.A., Synthetic Biologics, Inc., and Teva Pharmaceuticals Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Multiple Sclerosis Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment Modality, market is studied across Injectable Agents and Oral Agents.
  • Based on Application, market is studied across Hospital and Research.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Robust investment in research and development activities globally
      • 5.1.1.2. Favorable government support to increase the awareness among people
      • 5.1.1.3. Rising incidence of MS in young and elderly people
    • 5.1.2. Restraints
      • 5.1.2.1. Relatively high cost of the drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing preference for oral drugs such as Copaxone and Tysabri
      • 5.1.3.2. Emerging novel pipeline of drugs by key market players
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory policies for drug approval
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Multiple Sclerosis Market, by Treatment Modality

  • 6.1. Introduction
  • 6.2. Injectable Agents
  • 6.3. Oral Agents

7. Multiple Sclerosis Market, by Application

  • 7.1. Introduction
  • 7.2. Hospital
  • 7.3. Research

8. Americas Multiple Sclerosis Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Multiple Sclerosis Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Multiple Sclerosis Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Allergan PLC
  • 3. AstraZeneca PLC
  • 4. Bayer AG
  • 5. Biogen Inc.
  • 6. Eli Lilly and Company
  • 7. F. Hoffmann-La Roche AG
  • 8. GlaxoSmithKline PLC
  • 9. Merck & Co. Inc.
  • 10. Mylan N.V.
  • 11. Novartis AG
  • 12. Pfizer Inc.
  • 13. Sanofi S.A.
  • 14. Synthetic Biologics, Inc.
  • 15. Teva Pharmaceuticals Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. MULTIPLE SCLEROSIS MARKET RESEARCH PROCESS
  • FIGURE 2. MULTIPLE SCLEROSIS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. MULTIPLE SCLEROSIS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. MULTIPLE SCLEROSIS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. MULTIPLE SCLEROSIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. MULTIPLE SCLEROSIS MARKET DYNAMICS
  • TABLE 7. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY INJECTABLE AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY ORAL AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 14. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 16. ARGENTINA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 17. ARGENTINA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 18. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 19. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 20. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 21. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 22. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 23. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 25. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 27. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 28. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. AUSTRALIA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 31. AUSTRALIA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. CHINA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 33. CHINA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. INDIA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 35. INDIA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. INDONESIA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 37. INDONESIA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. JAPAN MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 39. JAPAN MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. MALAYSIA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 41. MALAYSIA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. PHILIPPINES MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 43. PHILIPPINES MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. SINGAPORE MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 45. SINGAPORE MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. SOUTH KOREA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 47. SOUTH KOREA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. TAIWAN MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 49. TAIWAN MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. THAILAND MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 51. THAILAND MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. VIETNAM MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 53. VIETNAM MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. DENMARK MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 58. DENMARK MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. EGYPT MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 60. EGYPT MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. FINLAND MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 62. FINLAND MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 64. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 66. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. ISRAEL MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 68. ISRAEL MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 70. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. NETHERLANDS MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 72. NETHERLANDS MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. NIGERIA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 74. NIGERIA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. NORWAY MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 76. NORWAY MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. POLAND MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 78. POLAND MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. QATAR MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 80. QATAR MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 82. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. SAUDI ARABIA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 84. SAUDI ARABIA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 88. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. SWEDEN MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 90. SWEDEN MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. SWITZERLAND MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 92. SWITZERLAND MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. TURKEY MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 94. TURKEY MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED ARAB EMIRATES MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED ARAB EMIRATES MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. MULTIPLE SCLEROSIS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 100. MULTIPLE SCLEROSIS MARKET, FPNV POSITIONING MATRIX, 2023